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Abstract
Background: Carcinoma of the male breast is responsible for less than 1% of all malignancies in men but the
incidence is rising. Invasive ductal carcinoma is the most common histological subtype while invasive lobular
carcinoma is responsible for only 1.5% of the total cases of which pleomorpic lobular carcinoma is an extremely
rare variant. We report the case of a gentleman with node positive, pleomorphic lobular carcinoma of the breast.
Case presentation: An elderly gentleman with a past history of type 2 diabetes and long term ethanol use
presented to us with a self-discovered palpable lump in the left breast. Physical examination revealed bilateral
gynaecomastia along with a well circumscribed subareolar mass and palpable lymphadenopathy in the ipsilateral
axilla. The breast nodule revealed atypical cells on fine needle aspiration biopsy and the patient underwent a
modified radical mastectomy after systemic surveillance was negative for metastatic disease. The lesion was
reported as grade III pleomorphic lobular carcinoma with a lack of E-cadherin expression on immunohistochemistry
and the neoplastic cells exhibited strong positivity for estrogen receptor in the absence of Her2 gene amplification.
Six out of the eleven dissected regional lymph nodes showed evidence of disease. The patient completed 4 cycles
of adjuvant chemotherapy without evidence of recurrent disease and was subsequently lost to follow up.
Conclusions: Although invasive lobular carcinomas comprise 12% of all female breast cancers, they are very rare in
males due to lack of acini and lobules in the normal male breast. Pleomorphic lobular carcinoma, an aggressive
variant of ILC is even rarer in males.
Chronic consumption of ethanol by our patient may have resulted in some degree of hepatic impairment with
resultant hyperestrogenism. This in theory may have been the cause of his gynaecomastia, resultant breast cancer
and is a plausible explanation for development of the invasive lobular subtype in a male. The prognosis and
clinicopatholocial features of pleomorphic lobular carcinoma in men are less clearly defined due to its rarity.
Additional studies are hence necessary to improve our understanding of this disease in males.
Keywords: Male breast cancer, Pleomorphic lobular carcinoma, E-cadherin

Background
Carcinoma of the male breast is a rare entity accounting
for 0.7% of all breast cancers [1]. Although the disease is
also responsible for less than 1% of all malignancies in
men, the incidence of male breast cancer has seen a rise
of about 26% over the past quarter of a century [1,2].
Risk factors similar to those observed for female breast
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cancers are responsible for pathogenesis. All histopathological variants seen in female breast cancer have been
observed [3,4]. Invasive ductal carcinoma is the most
common histological subtype accounting for approximately 85% of all cases. Male breast cancers are significantly more likely to exhibit hormone receptor expression
in comparison to female breast cancers [1,2,5]. Data
from the Surveillance, Epidemiology, and End Results
(SEER) database shows that only 1.5% of male breast
cancers are of the invasive lobular subtype while the
same histological variant is responsible for approximately 12% of carcinomas of the female breast [2].
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Herein we report the case of an elderly gentleman diagnosed with the pleomorphic variant of invasive lobular
carcinoma along with involvement of the ipsilateral axillary lymph nodes. Only three cases of this histopathological subtype have ever been reported in the male
breast and none thus far had shown metastasis to the regional draining lymph nodes.

Case presentation
A 68 year old Pakistani male was referred to the outpatient oncology clinic at our center with a three month
history of a self-discovered, progressively increasing
palpable lump in the left breast. He had sought medical
attention for increasing size of the lump with recent development of pain. His past history was significant for
type 2 diabetes and long term ethanol use. There was no
family history of breast disease.
Physical examination revealed bilateral gynaecomastia
along with a 3 × 3 cm sized, relatively well circumscribed
subareolar mass which was firm and mildly tender. The
overlying skin appeared normal. There was evidence of
palpable lymphadenopathy in the ipsilateral axilla.
Breast ultrasonogram confirmed bilateral gynaecomastia
along with an irregular, hypoechoic, non-compressible
mass in the subareolar region of the left breast with associated ipsilateral axillary adenopathy. The breast nodule
was subjected to fine needle aspiration biopsy (FNAB)
which revealed atypical cells, following which the patient
underwent baseline blood workup and complete staging
with computed tomographic (CT) imaging. His preoperative blood workup was essentially normal although liver
function tests did reveal a marginally elevated alanine
transaminase (ALT) at 64 IU/L. Serological tests for
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hepatitis B and C were negative and ultrasound of the liver
showed mild fatty infiltration. After a core biopsy confirmation of malignancy, he underwent a modified radical
mastectomy (MRM) with axillary lymph node dissection.
His postoperative course was uneventful except mild seroma formation at the surgical site (Figure 1).
Gross histopathology of the surgical specimen revealed
a firm greyish white vaguely circumscribed lesion just
beneath the nipple measuring 2.8 × 2.5 × 2 cm. Microscopically, an infiltrative tumor was identified which was
composed of discohesive sheets of pleomorphic cells.
Tumor cells showed moderate to marked nuclear pleomorphism along with moderate cytoplasm (Figure 2).
There was absence of an intraductal component whereas
gynaecomastia was evident in the surrounding breast tissue characterized by breast ducts lined by double layer
of epithelium with mild ductal hyperplasia. Breast acini
or lobules were not identified. The lesion was reported
as grade III on a scale of I to III according to modified
Bloom Richardson grading system with invasion of the
dermal lymphatics. Surgical margins were negative and
six of the eleven dissected axillary lymph nodes demonstrated evidence of disease. The tumor was pathologically staged as pT2pN2Mx.
Tumor cells were negative for E-cadherin immunostain (Figure 3) and thus based on morphology and
immunprofile a diagnosis of invasive lobular carcinoma,
pleomorphic variant was rendered. The neoplastic cells
were strongly positive for estrogen receptor expression
but only displayed weak positivity for expression of the
progesterone receptor. Her2-Neu staining by immunohistochemistry revealed a score of +1 and the Ki-67 proliferative index was 20-25%.

Figure 1 Computed tomographic image highlighting right sided gynaecomastia (yellow arrow) and left sided postoperative changes
with seroma formation.
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Figure 2 Photomicrographs of the tumor cells. Magnification; ×40: Tumor cells arranged in aggregates and as cords (A). Magnification; × 40:
Tumor cells exhibiting pleomorphic cells along with a focus of dermal lymphatic invasion (B).

The patient was recommended adjuvant chemotherapy
to be followed by chest wall and axillary irradiation and
hormonal therapy. He completed 4 cycles of adjuvant
chemotherapy without any evidence of recurrence and
was subsequently lost to followup.

Conclusions
Although the majority of men with breast cancer have
no identifiable risk factors, some risk factors that are
modestly unique to men include never being married,
gynecomastia, Klinefelter’s syndrome and a history of
testicular or liver pathology [6].
Breast cancers in men typically presents as a painless,
firm mass that is usually subareolar. The left breast is involved slightly more often than the right, and less than
one percent of cases are bilateral [7,8]. Male breast cancers tend to present sooner because of scarcity of breast

tissue and hence most subjects have early stage disease
at presentation.
Invasive lobular carcinoma (ILC) of the breast is a
histopathologically distinct entity from the much more
common invasive ductal carcinoma (IDC). Although invasive lobular carcinomas comprise 12% of all female
breast cancers, they are very rare in the male breast [1].
The rarity of a lobular histologic subtype of breast cancer is due to lack of acini and lobules in the normal male
breast [9]. Endogenous or exogenous estrogenic stimulation may induce the development of acini and lobules in
the male breast and hence subsequently increases the
theoretical risk of development of invasive lobular carcinoma (ILC). ILC typically lacks E-cadherin expression
on immunohistochemical (IHC) staining and negative
expression is now used as an aid in diagnosis [10].
Pleomorphic lobular carcinoma is an aggressive variant
of ILC with distinct histopathological features including
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Figure 3 Magnification; × 20: Negative E-cadherin immunostaining of tumor cells with positive internal control in skin adnexal structures.

marked pleomorphism and atypia along with a higher
proliferative index [11]. A higher incidence of HER2
gene amplification and a lower frequency of hormone
receptor expression are other features typical of the
pleomorphic variant when compared to its invasive
lobular counterpart [4]. This subtype was first described
in the female breast in 1992 by Eusebi et al. who also
highlighted the aggressive clinical course associated with
it [12]. Only 3 cases of this variant have been reported in
the male breast previously [4,10,13] but our case is
unique in that it is the first with evidence of regional
draining lymph nodal involvement. The clinical and
histopathological features of the 4 cases of pleomorphic
lobular carcinoma of the male breast described so far,
have been summarized in Table 1.

The present case merits discussion on several key
points. Ethanol use by this gentleman may have resulted
in some degree of hepatic impairment. It is an established fact that liver dysfunction results in hyperestrogenism which may have been the cause of his
gynaecomastia and resultant breast cancer [14]. The
hyperestrogenism theory also explains the development
of the invasive lobular subtype in this particular gentleman. The typical morphologic features of pleomorphic
lobular carcinoma and lack of E-cadherin expression
aided in this rare histopathological diagnosis. The clinical presentation, hormone receptor expression and the
absence of Her2 gene amplification was typical of what
is seen in male breast cancer. To the best of our knowledge, this is the first reported case of pleomorpic

Table 1 Clinical and histopathological features of pleomorphic lobular carcinoma of the male breast
Reference
Year of report

Maly et al.

Rohini et al.

Ishida et al.

10

4

13

Present case

2005

2010

2013

2013

Age

44

55

76

68

Site

Left

Left

Right

Left

Gynecomastia

No

No

Yes

Yes

Size (cm)

2.5 × 2.0

3.0 × 2.5

3.0 × 2.5

2.8 × 2.5

Estrogen receptor expression

+

Not mentioned

+

+

Progesterone receptor expression

+

Not mentioned

-

+

Her2 gene amplification

-

Not mentioned

-

-

Ki-67 proliferative index (%)

5

Not mentioned

12.7

20-25

E-cadherin immunostaining

-

-

-

-

Lymph node involvement
Followup

-

-

-

+

Disease free at 2 years

Disease free at 1 year

Disease free at 2 months

Disease free at 3.5 months
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lobular carcinoma in the male breast with regional
lymph node involvement. This may be attributed to a
delay on the part of the patient to seek appropriate
medical care in a resource poor country like Pakistan
where all medical expenses are incurred by patients
themselves.
ILC and particularly pleomorphic lobular carcinoma in
the male breast is a rare occurrence and reminds us to
tailor management according to subtype as this variant
is known to be clinically aggressive in females. The prognosis and clinicopatholocial features of this variant in
men are less clearly defined due to its rarity. Additional
studies are hence necessary to improve our understanding of this disease in males.

Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompanying
images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
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